The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group, the methylene hydrogen of which is replaced by a methoxycarbonyl group (the S enantiomer). A P2Y12 receptor antagonist, it is used to inhibit blood clots and prevent heart attacks.
ABCB1 gene affects the reaction [CYP2C19 gene affects the susceptibility to clopidogrel] clopidogrel results in decreased activity of ABCB1 protein ABCB1 gene affects the susceptibility to clopidogrel; ABCB1 gene polymorphism affects the susceptibility to clopidogrel; ABCB1 gene SNP affects the susceptibility to clopidogrel ABCB1 protein results in increased secretion of clopidogrel clopidogrel results in decreased expression of ABCB1 mRNA; clopidogrel results in decreased expression of ABCB1 protein ABCB1 protein results in decreased uptake of clopidogrel [Aspirin results in increased expression of ABCB1 protein] which results in decreased uptake of clopidogrel
clopidogrel inhibits the reaction [Adenosine Diphosphate results in increased expression of CD40LG protein] Clopidogrel inhibits the reaction [Adenosine Diphosphate results in increased expression of CD40LG protein]; Clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of CD40LG protein] clopidogrel results in decreased expression of CD40LG protein
CYP1A2 protein results in increased oxidation of and results in increased cleavage of clopidogrel metabolite; furafylline inhibits the reaction [CYP1A2 protein results in increased oxidation of clopidogrel]
CYP2B6 protein results in increased oxidation of clopidogrel [Clopidogrel co-treated with NR1I3 protein mutant form] results in increased expression of CYP2B6 mRNA Clopidogrel results in increased expression of CYP2B6 mRNA
ABCB1 gene affects the reaction [CYP2C19 gene affects the susceptibility to clopidogrel]; CYP2C19 gene affects the reaction [clopidogrel affects the phosphorylation of VASP protein]; CYP2C19 gene affects the susceptibility to [Adenosine Diphosphate co-treated with clopidogrel]; CYP2C19 gene polymorphism results in decreased metabolism of and results in decreased activity of clopidogrel; CYP2C19 gene SNP promotes the reaction [CYP2C19 gene SNP affects the susceptibility to clopidogrel]; CYP2C19 protein results in increased metabolism of and results in increased activity of clopidogrel; CYP2C19 protein results in increased oxidation of and results in increased cleavage of clopidogrel metabolite; CYP2C9 gene affects the reaction [CYP2C19 gene affects the susceptibility to clopidogrel]; N-3-benzylnirvanol inhibits the reaction [CYP2C19 protein results in increased oxidation of clopidogrel]; Omeprazole inhibits the reaction [CYP2C19 protein results in increased oxidation of clopidogrel]; P2RY12 gene SNP affects the reaction [CYP2C19 gene SNP affects the susceptibility to clopidogrel] CYP2C19 gene affects the susceptibility to clopidogrel; CYP2C19 gene polymorphism affects the susceptibility to clopidogrel; CYP2C19 gene SNP affects the susceptibility to clopidogrel CYP2C19 gene polymorphism affects the abundance of clopidogrel metabolite CYP2C19 gene polymorphism results in decreased metabolism of clopidogrel; CYP2C19 gene SNP results in decreased metabolism of clopidogrel CYP2C19 gene polymorphism results in decreased susceptibility to clopidogrel; CYP2C19 gene SNP results in decreased susceptibility to clopidogrel CYP2C19 gene polymorphism results in increased susceptibility to clopidogrel; CYP2C19 gene SNP results in increased susceptibility to clopidogrel CYP2C19 protein results in increased metabolism of clopidogrel
CYP2C9 gene affects the reaction [CYP2C19 gene affects the susceptibility to clopidogrel]; CYP2C9 protein results in increased oxidation of and results in increased cleavage of clopidogrel metabolite CYP2C9 gene SNP affects the susceptibility to clopidogrel CYP2C9 gene SNP results in decreased metabolism of clopidogrel
CYP3A5 gene polymorphism affects the susceptibility to Clopidogrel CYP3A5 protein results in increased oxidation of and results in increased cleavage of Clopidogrel metabolite
clopidogrel promotes the reaction [Silicon Dioxide analog results in increased expression of IL6 protein] clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein] IL6 protein results in increased susceptibility to clopidogrel clopidogrel results in decreased expression of IL6 mRNA
ITGA2 gene SNP affects the susceptibility to [Aspirin co-treated with clopidogrel co-treated with Adenosine Diphosphate]; ITGA2 gene SNP affects the susceptibility to [Aspirin co-treated with clopidogrel co-treated with Epinephrine]; ITGA2 gene SNP affects the susceptibility to [Aspirin co-treated with clopidogrel]
Clopidogrel inhibits the reaction [1-Naphthylisothiocyanate results in increased activity of MPO protein]; Clopidogrel inhibits the reaction [Lipopolysaccharides results in increased activity of MPO protein]
Clopidogrel affects the localization of NR1I3 protein mutant form [Clopidogrel co-treated with NR1I3 protein mutant form] results in increased expression of CYP2B6 mRNA; Clopidogrel binds to and results in increased activity of NR1I3 protein alternative form; Clopidogrel inhibits the reaction [ethyl (5-(diethylglycyl)-10,11-dihydro-5H-dibenzo(b,f)azepin-3-yl)carbamate results in decreased activity of NR1I3 protein]; Clopidogrel promotes the reaction [MED1 protein binds to NR1I3 protein alternative form]
clopidogrel results in decreased expression of OCLN protein SB 203580 inhibits the reaction [clopidogrel results in decreased expression of OCLN protein]
clopidogrel binds to and results in decreased activity of P2RY12 protein; P2RY12 gene SNP affects the reaction [CYP2C19 gene SNP affects the susceptibility to clopidogrel] P2RY12 gene affects the susceptibility to clopidogrel; P2RY12 gene SNP affects the susceptibility to clopidogrel; P2RY12 protein affects the susceptibility to clopidogrel P2RY12 protein results in increased susceptibility to clopidogrel
PON1 gene polymorphism affects the susceptibility to clopidogrel PON1 protein results in increased metabolism of and results in increased activity of clopidogrel
Clopidogrel inhibits the reaction [F2 protein results in increased expression of SELP protein]; Clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of SELP protein] clopidogrel results in decreased expression of SELP mRNA; clopidogrel results in decreased expression of SELP protein
clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of TGFB1 mRNA] clopidogrel results in increased expression of TGFB1 mRNA
clopidogrel results in increased expression of THBS1; clopidogrel results in increased expression of THBS1 mRNA; clopidogrel results in increased expression of THBS1 protein
clopidogrel results in decreased expression of TJP1 protein SB 203580 inhibits the reaction [clopidogrel results in decreased expression of TJP1 protein]
clopidogrel results in increased expression of TNF mRNA Clopidogrel inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]
browse the term
